Clinical trial
Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients…
NCT01395810 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT01395810 |
|---|---|
| Title | Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 |
| Official title | Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B |
| Acronym | paradigm™ 4 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Haemophilia B |
| Intervention type | Drug |
| Interventions | nonacog beta pegol |
| Enrollment | 71 |
| Start date | Apr 15, 2012 |
| Primary completion | Mar 30, 2014 |
| Completion | Mar 30, 2014 |
| First posted | Jul 18, 2011 |
| Last update posted | May 9, 2018 |
| Countries | Austria, France, Germany, Greece, Italy, Japan, Malaysia, Netherlands, North Macedonia, Romania, Russia, South Africa and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: